Bibliografia

1. Bergqvist D, Hedelin H, Lindblad B, et al. Abdominal Injuries in children: an analysis of 348 cases. Injury 1985; 16: 217-20.

 

2. Bergqvist D, Hedelin H, Karlsson G, Lindblad B Matzsch T. Abdominal trauma during thirthy years. Analysis of a large case series. Injury 1981; 13: 93-9.

 

3. Bergqvist D, Hedelin H, Karlsson G, Lindblad B, Mätzsch T. Abdominal injury from sporting activities. Br J Sports Med 1982; 16: 76-9.

 

4. Schneider RE. Genitourinary trauma. Emerg Med Clin North Am 1993; 11: 137-45.

 

5. Zink RA, Muller-Mattheis V, Oberneder R. Results of the West German multicenter study “Urological traumatology”. Urologe A 1990; 29: 243-50.

 

6. Brophy RH, Gamradt SC, Barnes RP, et alF. Kidney injuries in professional American football: implications for management of an athlete with 1 functioning kidney. Am J Sports Med 2008; 36: 85-90.

 

7. Miller KS, McAninch JW. Radiographic assessment of renal trauma: our 15-year experience. J Urol 1995; 154: 352-5.

 

8. McAndre JD, Corriere JN. Radiographic evaluation of renal trauma: evaluation of 1103 consecutive patients. Br J Urol 1994; 73: 352-4.

 

9. Moore EE, Shackford SR, Pachter HL, et al. Organ injury scaling: spleen, liver, and kidney. J Trauma 1989; 29: 1664-6.

 

10. Wan J, Corvino TF, Greenfield SP, Di Scala C. Kidney and testicle injuries in team and individual sports: data from the national paediatric trauma registry. J Urol 2003; 170: 1528- 32.

 

11. McAleer IM, Kaplan GW. Pediatric genitourinary trauma. Urol Clin North Am 1995; 22: 177-88.

 

12. Gerstenbluth RE, Spirnak JP, Elder JS. Sports participation and high grade renal injuries in children. J Urol 2002; 168: 2575-8.

 

13. Holmes FC, Hunt JJ, Sevier TL. Renal injury in sport. Curr Sports Med Rep 2003; 2: 103-9.

 

14. Campbell EW, Filderman PS, Jacobs SC. Ureteral injury due to blunt and penetrating trauma. Urology 1992; 40: 216-20.

 

15. Presti JC, Carroll PR, McAninch JW. Ureteral and renal pelvic injuries from external trauma: diagnosis and management. J Trauma 1989; 29: 370-4.

 

16. Grossman JA, Kulund DN , Miller CW, Winn HR, Hodge RH Jr. Equestrian injuries. Results of a prospective study. JAMA 1978; 240: 1881-2.

 

17. Corriere JN, Sandler CM. Mechanisms of injury: Patterns of extravasation and management of extraperitoneal bladder rupture due to blunt trauma. J Urol 1988; 139: 43-4.

 

18. Cass AS. Diagnostic studies in bladder rupture: Indications and techniques. Urol Clin North Am 1989; 16: 267-73.

 

19. McConnell JD, Wilkerson MD, Peters PC. Rupture of the bladder. Urol Clin North Am 1982; 9: 293-96.

 

20. Carroll PR, Mc Aninch JW. Major bladder trauma: mechanism of injury and a unified method of diagnosis. J Urol 1984; 132: 254-7.

 

21. Horstman WG, McClennan BL, Heiken JP. Comparison of computed tomography and conventional cystography for detection of traumatic bladder rupture. Urol Radiol 1991; 12: 188-93.

 

22. Corriere JN, Sandler CM. Management of the ruptured bladder: Seven years of experience with 111 cases. J Urol 1986; 26: 830-3.

 

23. Palmer JK, Benson GC, Corriere JN. Diagnosis and initial management of urological injuries associated with 200 consecutive pelvic fractures. J Urol 1983; 130: 712-14.

 

24. Koraitim MM, Marzouk ME, Orabi SS. Risk factors and mechanism of urethral injury in pelvic fractures. Br J Urol 1996; 77: 876-80.

 

25. Cass AS, Gleich P, Smith C. Simultaneous bladder and prostatomembranous urethral rupture from external trauma. J Urol 1984; 132: 907-11.

 

26. Cass AS, Godec CJ. Urethral injury due to external trauma. Urology 1978; 11: 607-11.

 

27. Park S, McAninch JW. Straddle injuries to the bulbar urethra: management and outcomes in 78 patients. J Urol 2004; 171(2 Pt 1): 722-5.

 

28. Lin PHC, Chng HC. Initial management of acute urethral injuries. Br J Urol 1989; 64: 165-8.

 

29. McAninch JW. Traumatic injuries to the urethra. J Trauma 1981; 21: 291-7.

 

30. Webster GD, Mathes GL, Selli C. Prostatomembranous urethral injuries: a review of the literature and a rational approach to their management. J Urol 1983; 130: 898-902.

 

31. Brandes S. Initial management of anterior and posterior urethral injuries. Urol Clin North Am 2006; 33(1): 87-95.

 

32. Delaney DP, Carr MC. Urethral strictures incident to bicycle motocross racing. Urology 2005; 65(4): 798.

 

33. Leibovitch I, Mor Y. The vicious cycling: bicycling related urogenital disorders. Eur Urol 2005 Mar; 47(3): 277-86.

 

34. Golash A, Gray R, Ruttley MS, Jenkins BJ. Traumatic priapism: an unusual cycling injury. Br J Sports Med 2000; 34(4): 310-1.

 

35. De Rose AF, Giglio M, De Caro G, et al. Arterial priapism and cycling: a new worrisome reality? Urology 2001; 58(3): 462.

 

36. Shankar KR, Babar S, Rowlands P, Jones MO. Posttraumatic high-flow priapism: treatment with selective embolisation. Pediatr Surg Int 2000; 16: 454-6.

 

37. Rico Lopez J, Amaya Gutierrez J, Blasco Hernandez P, et al. Post traumatic high-flow priapism in prepubertal age. Actas Urol Esp 1998; 22: 531-7.

 

38. Miller SF, Chait PG, Burrows PE, et al. Post-traumatic arterial priapism in children: management with embolization. Radiology 1995; 196: 59-62.

 

39. Benchekroun A, Iken A, Kasmaoui E, et al. Scrotal injuries. Report of 40 cases. Ann Urol (Paris) 2001; 35: 349-52.

 

40. Lawson JS, Rotem T, Wilson SF. Catastrophic injuries to the eyes and testicles in footballers. Med J 1995; 163: 242-4.

 

41. Adams RJ, Attia M, Cronan K. Report of 4 cases of testicular rupture in adolescent boys secondary to sports-related trauma. Pediatr Emerg Care 2008; 24(12): 847-8.

 

42. Altarac S. Management of 53 cases of testicular trauma. Eur Urol 1994; 25: 119-23.

 

43. Cass-5 AS, Luxenberg M. Value of early operation in blunt testicular contusion with hematocele. J Urol 1988; 139: 746-47.

 

44. Azadzoi KM, Babayan RK, Kozlowski R, Siroky MB. Chronic ischemia increases prostatic smooth muscle contraction in the rabbit. J Urol. 2003; 170: 659-63.

 

45. Kozlowski R, Kershen RT, Siroky MB, Krane RJ, Azadzoi KM. Chronic ischemia alters prostate structure and reactivity in rabbits. J Urol 2001; 165: 1019-26.

 

46. Nickel JC. Prostatitis - Old questions, new answers: an update for clinicians. 2007.

 

47. Turner JA, Hauge S, Korff MV, et al. Primary care and urology patients with the male pelvic pain syndrome: symptoms and quality of life. J Urol 2002; 167: 1768-73.

 

48. Giubilei G, Mondaini N, Minervini A,et al. Physical activity of men with chronic prostatitis/chronic pelvic pain syndrome not satisfied with conventional treatments—could it represent a valid option? The physical activity and male pelvic pain trial: a double-blind, randomized study. J Urol 2007; 177: 159-65.

 

49. Di Luigi L, Romanelli, F, Pigozzi F, et al. Role of sport medicine in andrological prevention. Med Sport 1994; 47: 665-70.

 

50. Di Luigi L, Gentile V, Pigozzi F, et al. Physical activity as a possible aggravating factor for athletes with varicocele: impact on the semen profile. Hum Reprod 2001; 16(6): 1180-4.

 

51. Scaramuzza, A., Tavana, R. Marchi, A. Varicocele in young soccer players. Lancet 1996; 348: 1180-1.

 

52. De Souza MJ, Miller BE. The effect of endurance training on reproductive function in male runners. Sports Med 1997; 23: 357-74.

 

53. De Souza MJ, Arce JC, Pescatello LS, et al. Gonadal hormones and semen quality in male runners. Int J Sports Med 1994; 15: 383-91.

 

54. Arce JC, De Souza MJ, Pescatello LS, et al. Subclinical alterations in hormone and semen profile in athletes. Fertil Steril 1993; 59: 398-404.

 

55. Roberts AC, McClure RD, Weiner RI, et al. Overtraining affects male reproductive status. Fertil Steril 1993; 60: 686-92.

 

56. Nasrallah P, Nair G, Congeni J, Bennett CL, McMahon D. Testicular health awareness in pubertal males J Urol 2000; 164(3 Pt 2): 1115-7.

 

57. Rigano E, Santoro G, Impellizzeri P, et al. Varicocele and sport in the adolescent age. Preliminary report on the effects of physical training. J Endocrinol Invest 2004; 27(2): 130-2.

 

58. Goel R, Majeed F, Vogel R, et al. Exercise-induced hypertension, endothelial dysfunction, and coronary artery disease in a marathon runner. M. Am J Cardiol 2007; 99(5): 743-4.

 

59. Marceau L, Kleinman K, Goldstein I, McKinlay J. Does bicycling contributeto the risk of erectile dysfunction? Results from the Massachusetts Male Aging Study (MMAS). Int J Impot Res 2001; 13: 298-302.

 

60. Schwarzer U, Sommer F, Klotz T, Cremer C, Engelmann U. Cycling and penile oxygen pressure: the type of saddle matters. Eur Urol 2002; 41(2): 139-43.

 

61. Gemery JM, Nangia AK, Mamourian AC, Reid SK. Digital three-dimensional modelling of the male pelvis and bicycle seats: impact of rider position and seat design on potential penile hypoxia and erectile dysfunction. BJU Int 2007; 99(1): 135-40.

 

62. Ricchiuti VS, Haas CA, Seftel AD, Chelimsky T, Goldstein I. Pudendal nerve injury associated with avid bicycling. J Urol 1999; 162: 2099-100.v

     

63. Leibovitch I, Mor Y. The vicious cycling: bicycling related urogenital disorders. Eur Urol 2005; 47: 277-87.

 

64. Casarico A, Pescatori ES. LUTS/IPB and male sexual dysfunctions: evidence based data. GIMSeR 2006; 13: 19-36.

 

65. Holly J, Perks C. Growth hormone and cancer: are we asking the right questions? Clin Endocrinol 2006; 64: 122-4.

 

66. Calfee R, Fadale P. Popular ergogenic drugs and supplements in young athletes: Pediatrics 2006; 117: 577-89.

 

67. Wroken M. Drug use and abuse in sport. In: Mottram DR (ed). Drugs in sport. 4th ed. London: Mottram DR, 2006; p.29-64 (Chapter 2).

 

68. Silver MD. Use of ergogenic aids by athletes. J. Am Acad Orthop Surg. 2001; 9: 61-70.

 

69. Bahrke MS, Yesalis CE, Brower KJ. Anabolic-androgenic steroid abuse and performance-enhancing drugs among adolescents. Child Adols Psychiatr Clin N Am1998; 7 (4): 821-38.

 

70. Wood J. Anabolic steroids: a fatal attraction? J Neuroendocrin 2006; 18: 227-228.

 

71. Saugy M, Robinson N, Saudan C, et al. Human growth hormone doping in sports. Br J Sports Med 2006; 40 (Suppl 1): S35-39.

 

72. Goldman B. Liver carcinoma in an athlete. Ann Int Med 1984; 100: 158-9 .

 

73. Overly WL, Dankoff JA, Wang BK, Singh UD. Androgens and hepatocellular carcinoma in an athlete. Ann Int Med 1984; 100: 158-9.

 

74. Creagh TM, Rubin A, Evans DJ. Hepatic tumours induced by anabolic steroids in an athlete. J Clin Pathol 1988; 41: 441-3.

 

75. Bagia S, Ewuitt PM, Morris DL. Anabolic steroid-induced hepatic adenomas with spontaneous haemorrhage in a body builder. Aus NZJ Surg 2000; 70: 686-7.

 

76. Socas L, Zumbado M, Perz-Luzardo O, et al. Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: a report of two cases and a review of the literature. Br J Sports Med 2005; 39: e27.

 

77. Snyder PJ. Androgens. In: Brunton LL, Lazo JS, Parker KL (eds). The pharmacological basis of therapeutics. 11th ed. New York : Goodman & Gilman’s, 2005; p. 1573-85.

 

78. George AJ. Androgenic anabolic steroids. In: Mottram DR; 2006; 140-185 (Chapter 5).

 

79. Prat J, Gray GF, Stolley PD, Coleman JW. Wilms tumor in an adult associated with androgen abuse. JAMA 1977; 237: 2322-3.

 

80. Parsinem M, Seppala T. Steroid use and long-term health risk in former athletes. Sports Med 2002; 32: 83-94.

 

81. Bryden AA, Rothwell PJ, O’Reeilly PH. Anabolic steroid abuse and renal-cell carcinoma. Lancet 1995; 346: 1306-7.

 

82. 82.Martorana G, Concetti S, Manferrari F, Creti S. Anabolic steroid abuse and renal cell carcinoma. J Urol 1999; 162: 2089.

 

83. Roberts JT, Essenigh DM. Adenocarcinoma of prostate in 40-years old body-builder. Lancet 1986; 2: 742.

 

84. Street C, Antonio J, Cudlipp D. Androgen use by athletes: a reevaluation of the health risks. Can J Appl Physiol 1996; 21: 421-40.

 

85. Froehner M, Fischer R, Leike S, et al. Intratesticular leiomyosarcoma in a young man after high dose doping with oral-turinabol. A case report. Cancer 1999; 86: 1571-5.

 

86. Parsinen M, Kujala U, Vartiainen E, Sarna S, Seppala T. Increased premature mortality of competitive powerlifters aspected to have used anabolic agents. Int J Sports Med 2000; 21: 225-7.

 

87. Emerman JT, Leahy M, Gout PW, Bruchovsky N. Elevated growth hormone levels in sera from breast cancer patients. Horm Metab Res 1985; 16: 421-4.

 

88. Peyrat JB, Bonneterre J, Hecquet B, et al. Plasma insulin like growth factor 1 (IGF-1) concentrations in human breast cancer. Eur J Cancer 1993; 29A: 492-7.

 

89. Hankinson SE, Willet WC, Colditz GA et al. Circulating concentrations of insuline-like growth factot 1 and risk of breast cancer. Lancet 1998; 351: 1393-6.

 

90. Chan JM, Stampfer MJ, Giovannucci E et al. Plasma insuline-like growth factor 1 and prostate cancer risk: a prospective study. Science 1998; 279: 563-6.

 

91. Yu H, Spitz MR, Mistry J, et al. Plasma levels of insuline-like growth factor 1 and lung cancer risk: a case-control study. J Natl Cancer Inst 1999; 91: 151-6.

 

92. Ma J, Pollak MN, Giovannucci E et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF-1) and IGF-binding protein-3, J Natl Cancer Inst 1999; 91: 620-5.

 

93. Jenkins PJ, Besser M. Clinical perspective: acromegaly and cancer, a problem. J Clin Endocr and Metab 2001; 86: 2935-41.

 

94. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004; 4: 505-18.

 

95. Larsson O, Girnita A, Girnita L. Role of insuline-like growth factor 1 receptor signalling in cancer. Br J Cancer 2005; 92: 2097-101.

 

96. Mitsiades CS, Mitsiades N. Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signalling. Expert Rev Anticancer Ther 2005; 5: 487-99.

 

97. Akagi Y, Liu W, Zebrowsky B, Xie K, Ellis LM. Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor -1. Cancer Res 1998; 58: 4008-14.

 

98. Jenkins PJ, Mukherjee A, Shalet SM. Does growth hormone cause cancer? Clin Endocrinol 2006; 64: 115-21.

 

99. Mills JL, Schnberger LB, Wysowsky DK, et al. Long-term mortality in the United States cohort of pituitary-derived growth hormone recipients. J Pediatr 2004; 144: 430-6.

 

100. Svensson J, Bengtsson BA, Rosen T, Oden A, Johansson G. Malignant disease and cardiovascular morbidity in hypopitutary adults with or without growth hormone replacement therapy. J Clin Endocrinol Metab 2004; 89: 3306-12.

 

101. Hardee ME, Arcasoy MO, Blachwell KL, Kirkpatrick JP, Dewhirs MW. Erythropoietin biology in cancer. Clin Cancer Res 2006; 12: 332-9.

 

102. Yasuda Y, Fujita Y, Matsuo T et al. Erythropietin regulates tumor growth of human malignancies. Carcinogenesis 2003; 24: 1021-9.

 

103. Carlini RG, Dusso AS, Obilao CI, Alvarez UM, Rothstein M. Recombinant human erythropietin (rHuEPO) increases endothelin-1 release by endothelial cells. Kidney Int 1993; 43: 1010-4.

 

104. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomized, doubleblind, placebo-controlled trial. Lancet 2003; 362: 1255-60.

 

105. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal haemoglobin levels with epoietin a in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005; 23: 5960-72.

 

106. Michael U, Jackisch C, Lenhard MS, et al. Epoietin-49. alpha reduces red blood cell transfusion (RBC) in high risk breast cancer patients with adjuvant dose-dense, sequential chemotherapy with epirubicin (E), paclitaxel (T) and cyclophosphamide (ETC). 41 st Annual Meeting of the American Society of Clinical Oncology, May 13-17, 2003. J Clin Oncol 2005; 23: 613 (Abstract).

 

107. Blohmer JU, Wurschmid F, Petry U, et al. Results with sequential adjuvant chemo-radiotherapy with vs without epoietin alfa for patients with high risk cervical cancer: results of a prospective, randomized, open and controlled AGO- and NOGGO-intergropup study. 29 th European Society for Medical Oncology Congress, 29 October to 2 November 2004. Ann Oncol 2004; 15 (Suppl. 3): 447 PD (Abstract).

 

108. Thiblin I, Petersson A. Pharmacoepidemiology of anabolic androgenic steroids: a review. Fundam Clin Pharmacol 2005; 19: 27-44.

 

109. Dehm SM, Tindall DJ. Molecular regulation of androgen action in prostate cancer. J Cell Biochem 2006; 99: 333-44.

 

110. Mabjeesh NJ, Willard MT, Frederickson CE, Zhong H, Simons JW. Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3’-kinase/protein kinase B in prostate cancer cells. Clin Cancer Res 2003; 9: 2416-25.

 

111. Mayer D, Forstner K. Impact of dehydroepiandrosterone on hepatocarcinogenesis in the rat. Int J Oncol 2004; 25: 1021-30.

 

112. Leung G, Tsao SW, Wong YC. Sex hormone-induced mammary carcinogenesis in female Noble rats: detection of differentially expressed genes. Breast Cancer Res Treat 2003; 77:49-63.

 

113. Shirai T, Takahashi S, Cui L et al. Experimental prostate carcinogenesis-rodent models. Mut Res 2000; 462: 219-26.

 

114. Bronson FH, Matherne CM. Exposure to anabolic-androgenic steroids shorteness life span of male mice. Med Sci Sports Exerc 1997; 29: 615-9.

 

115. Severi G, Morris HA, MacInnis RJ et al. Circulating steroid hormones and the risk of prostate cancer. Cancer Epidem Biomarkers Prev 2006; 15: 86-91.

 

116. Committee on Sports Medicine and Fitness. Adolescents and anabolic steroids: a subject review. American Accademy of Pediatrics. Pediatrics 1997; 99: 904-8.

 

117. Dawson RT . Drugs in sport – the role of the physician. J Endocrinol 2001; 170: 55-61.